Posted Sep. 8, 2010 at 11:51 a.m.

GSK to sell R&D center in Croatia, signs production deal in U.K.

Print this blog post

Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – GlaxoSmithKline (NYSE: GSK) is selling a research and development facility in Croatia and has signed a new production contract for drugs in the U.K. where it continues to plan to build a new plant.

The moves, along with the naming of a new chief financial officer also on Wednesday, are the latest in a series made by Chief Executive Officer Andrew Witty as he continues to reorganize and refocus the drug giant.

GSK is selling the R&D facility in Zagreb, Croatia, to Galapagos.

Financial terms were not disclosed. However, GSK did sign a three-year fee-for-service agreement with Galapagos worth some $20 million.

Approximately 130 GSK workers will be transferred to Galapagos.

For more details, read here.

In the U.K., meanwhile, GSK signed a production agreement with Lonza for five early stage antibodies that are currently in Phase I and II clinical trials.

GSK also is working with Lonza in assessing options for a new biopharmaceutical manufacturing facility to be built within the U.K.

For details, read here.

GSK maintains its U.S. headquarters in RTP.

Get the latest news alerts: Follow LTW at Twitter.
 

Copyright 2012 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Featured